Literature DB >> 27599666

Low acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?

Altan Onat1, Servet Altay2, Murat Yüksel3, Yusuf Karadeniz4, Günay Can5, Hüsniye Yüksel6, Evin Ademoğlu7.   

Abstract

OBJECTIVE: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation.
METHODS: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as "healthy."
RESULTS: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in "healthy" men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values ≥22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF <22 nmol/L. In linear regression analyses in the whole sample, ASP was inversely associated independently with PAF and PAF-AH and, in men, positively with Lp(a) and sex hormone-binding globulin. Prevalent and (at 2.0 years' follow-up) incident metabolic syndrome (MetS, n=393), diabetes (n=154), and coronary heart disease (CHD, n=171) were analyzed by sex-, age-, and Lp(a)-adjusted logistic regression, using tertiles of ASP and PAF. The lower two (<42 nmol/L) ASP tertiles were a risk factor in combined sexes for MetS and diabetes. In women, incident CHD was predicted by either reduced or elevated ASP tertiles.
CONCLUSION: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for "reduced" values and increased likelihood of cardiometabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27599666      PMCID: PMC5336773          DOI: 10.14744/AnatolJCardiol.2016.7024

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


  32 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 2.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

Review 3.  Complement C3 and cleavage products in cardiometabolic risk.

Authors:  Altan Onat; Günay Can; Reza Rezvani; Katherine Cianflone
Journal:  Clin Chim Acta       Date:  2011-03-15       Impact factor: 3.786

4.  Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance.

Authors:  Zeki Yesilova; Metin Ozata; Cagatay Oktenli; Sait Bagci; Ayhan Ozcan; S Yavuz Sanisoglu; Ahmet Uygun; Halil Yaman; Necmettin Karaeren; Kemal Dagalp
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

5.  Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.

Authors:  M Ozata; D Gungor; M Turan; G Ozisik; N Bingol; T Ozgurtas; I C Ozdemir
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 6.  Platelet-activating factor and related lipid mediators.

Authors:  S M Prescott; G A Zimmerman; D M Stafforini; T M McIntyre
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

7.  Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome.

Authors:  Yuwen Wu; Jianhua Zhang; Yu Wen; Hongwei Wang; Muxun Zhang; Katherine Cianflone
Journal:  Fertil Steril       Date:  2008-01-18       Impact factor: 7.329

8.  Change in plasma acylation stimulating protein during euglycaemic-hyperinsulinaemic clamp in overweight and obese postmenopausal women: a MONET study.

Authors:  David H St-Pierre; Katherine Cianflone; Jessica Smith; Lise Coderre; Antony D Karelis; Pascal Imbeault; Jean-Marc Lavoie; Rémi Rabasa-Lhoret
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-13       Impact factor: 3.478

9.  Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome.

Authors:  Cagatay Oktenli; Taner Ozgurtas; Murat Dede; Yavuz S Sanisoglu; Mufit C Yenen; Zeki Yesilova; Levent Kenar; Yasemin G Kurt; Iskender Baser; Jessica Smith; Katherine Cianflone
Journal:  Gynecol Endocrinol       Date:  2007-12       Impact factor: 2.260

Review 10.  Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.

Authors:  Moses Eisaf; Alexandros D Tselepis
Journal:  Biochem Pharmacol       Date:  2003-12-01       Impact factor: 5.858

View more
  1 in total

1.  Complement Properdin Regulates the Metabolo-Inflammatory Response to a High Fat Diet.

Authors:  Rόisín C Thomas; Ramiar Kheder; Hasanain Alaridhee; Naomi Martin; Cordula M Stover
Journal:  Medicina (Kaunas)       Date:  2020-09-22       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.